Pathogenesis of Pulmonary Diseases
COPD is a slowly progressive condition characterized by airflow limitation, which is largely irreversible. It is characterized and defined by limitation of expiratory airflow. The current scenario is chronic airflow limitation results from an abnormal inflammatory response to inhaled particles and gases in the lung. The inflammatory mediators, including oxidants and proteases, are believed to play a major role in causing lung injury. Pathogenesis of COPD-an imbalance between proteases and antiproteases and an imbalance between oxidants and oxidative stress in the lungs. The pathological process of chronic lung disease is based on the concept that pulmonary diseases involve stages of commencement by pollutants, infectious agents and exposure to smoke, consolidation and progression. Tissue damage involves complex interactions among oxidative stress, chronic inflammation, extracellular matrix proteolysis, and apoptotic and autophagic cell death.
- Apoptosis
- Hyperinflation
- Inflammation
- Vasoconstriction
- Emphysema
Related Conference of Pathogenesis of Pulmonary Diseases
5th International Conference on Tuberculosis, Lung Health and Respiratory Diseases
17th International Conference on Chronic Obstructive Pulmonary Disease
14th International Conference on COPD Clinical Trials & Lung Care Advances
16th International Conference on Pulmonary & Respiratory Medicine
Pathogenesis of Pulmonary Diseases Conference Speakers
Recommended Sessions
Related Journals
Are you interested in
- Advances in Tuberculosis Diagnosis, Treatment, and Prevention - Tuberculosis-2025 (France)
- Asthma - Pulmonary Meet 2025 (France)
- Asthma and COPD - COPD_2025 (Spain)
- Chronic Bronchitis - Pulmonary Meet 2025 (France)
- Chronic Obstructive Pulmonary Disease - COPD_2025 (Spain)
- Co-Morbidities of COPD - COPD_2025 (Spain)
- Community-based Approaches to TB and Lung Health Awareness - Tuberculosis-2025 (France)
- COPD - Pulmonary Meet 2025 (France)
- COPD and Cardiovascular Diseases - COPD_2025 (Spain)
- COPD Complications - COPD_2025 (Spain)
- COPD Exacerbations - COPD_2025 (Spain)
- COPD Pathogenesis - COPD_2025 (Spain)
- COPD Therapeutics - COPD_2025 (Spain)
- COPD: Sign and Symptoms - COPD_2025 (Spain)
- Cystic Fibrosis - Pulmonary Meet 2025 (France)
- Depression and anxiety in COPD - COPD_2025 (Spain)
- Digital Health Technologies for Respiratory Disease Management - Tuberculosis-2025 (France)
- Drug Discovery of COPD - COPD_2025 (Spain)
- Early Diagnosis and Biomarkers in Respiratory Diseases - Tuberculosis-2025 (France)
- Emerging Respiratory Threats and Pandemic Preparedness - Tuberculosis-2025 (France)
- Emphysema - Pulmonary Meet 2025 (France)
- Epidemiology of COPD - COPD_2025 (Spain)
- Genetic risk factor of COPD - COPD_2025 (Spain)
- Genetics and Susceptibility to Tuberculosis and Lung Diseases - Tuberculosis-2025 (France)
- Global Efforts to Eliminate Tuberculosis by 2030 - Tuberculosis-2025 (France)
- Hospital-acquired Infections and Respiratory Care - Tuberculosis-2025 (France)
- Impact of Smoking and Environmental Factors on Lung Health - Tuberculosis-2025 (France)
- Infectious Respiratory Diseases - Pulmonary Meet 2025 (France)
- Interstitial lung disease - Pulmonary Meet 2025 (France)
- Latent Tuberculosis: Diagnosis, Treatment, and Control - Tuberculosis-2025 (France)
- Lung cancer - COPD_2025 (Spain)
- Lung Cancer - Pulmonary Meet 2025 (France)
- Lung Health: Emerging Trends and Challenges - Tuberculosis-2025 (France)
- Lung problems - Pulmonary Meet 2025 (France)
- Lung transplantation - Pulmonary Meet 2025 (France)
- Multidrug-Resistant Tuberculosis (MDR-TB) and Novel Therapies - Tuberculosis-2025 (France)
- Neonatal and Maternal Respiratory Health - Tuberculosis-2025 (France)
- Novel Therapies and Drug Development for Tuberculosis - Tuberculosis-2025 (France)
- Pathophysiology of COPD - COPD_2025 (Spain)
- Pediatric Pulmonary, Critical care and Sleep - COPD_2025 (Spain)
- Pediatric Tuberculosis and Respiratory Health - Tuberculosis-2025 (France)
- Pleural Diseases - Pulmonary Meet 2025 (France)
- Prevention and Control of Respiratory disease - Pulmonary Meet 2025 (France)
- Pulmonary diseases-treatment and therapies - COPD_2025 (Spain)
- Pulmonary Hypertension - Pulmonary Meet 2025 (France)
- Pulmonary Hypertension - COPD_2025 (Spain)
- Pulmonary Rehabilitation - Pulmonary Meet 2025 (France)
- Pulmonary Rehabilitation and Holistic Care for Respiratory Diseases - Tuberculosis-2025 (France)
- Pulmonary vascular disease - Pulmonary Meet 2025 (France)
- Pulmonology - Pulmonary Meet 2025 (France)
- Respiratory Disorders - Pulmonary Meet 2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Infections and Global Public Health Concerns - Tuberculosis-2025 (France)
- Respiratory Tract Infections - Pulmonary Meet 2025 (France)
- Role of Artificial Intelligence in Tuberculosis Diagnosis - Tuberculosis-2025 (France)
- Self-Management and Prevention of COPD - COPD_2025 (Spain)
- Sleep-Related Respiratory Disorders - Pulmonary Meet 2025 (France)
- Tuberculosis - Pulmonary Meet 2025 (France)
- Tuberculosis and HIV Co-infection: Challenges and Treatment - Tuberculosis-2025 (France)
- Tuberculosis Prevention and Global Public Health Strategies - Tuberculosis-2025 (France)
- Types of COPD - COPD_2025 (Spain)